Stock XTLB XTL BIOPHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials XTL Biopharmaceuticals Ltd.

Equities

XTLB

IL0010854979

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:55:00 15/05/2024 pm IST 		5-day change 1st Jan Change
10.1 ILa 0.00% Intraday chart for XTL Biopharmaceuticals Ltd. +9.78% +188.57%
30/04 XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
29/04 Top Premarket Gainers MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 8.814 7.005 15.68 14.99 6.363 5.28
Enterprise Value (EV) 1 0.6923 0.2773 9.639 8.867 2.642 3.274
P/E ratio 2.95 x -5.2 x -20.1 x 39.2 x -4.72 x -2.96 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -0.87 x - -10.2 x -8.61 x -3.01 x -4.29 x
EV / FCF -1.44 x -0.48 x -19.4 x -13.4 x -4.77 x -7.96 x
FCF Yield -69.3% -207% -5.15% -7.45% -21% -12.6%
Price to Book 1.06 x 1 x 2.51 x 2.83 x 1.59 x 2.38 x
Nbr of stocks (in thousands) 5,14,206 5,14,206 5,14,206 5,41,406 5,44,906 5,44,906
Reference price 2 0.0171 0.0136 0.0305 0.0277 0.0117 0.009690
Announcement Date 11/03/19 12/03/20 15/03/21 30/03/22 22/03/23 30/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -0.792 - -0.947 -1.03 -0.879 -0.764
EBIT 1 -0.793 -0.842 -0.948 -1.031 -0.88 -0.765
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 2.986 -1.347 -0.782 0.435 -1.348 -1.782
Net income 1 2.986 -1.347 -0.782 0.435 -1.348 -1.782
Net margin - - - - - -
EPS 2 0.005807 -0.002619 -0.001520 0.000706 -0.002473 -0.003270
Free Cash Flow 1 -0.4796 -0.5732 -0.4965 -0.6604 -0.554 -0.4111
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/03/19 12/03/20 15/03/21 30/03/22 22/03/23 30/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 8.12 6.73 6.04 6.13 3.72 2.01
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.48 -0.57 -0.5 -0.66 -0.55 -0.41
ROE (net income / shareholders' equity) 50% -17.6% -11.8% 9.73% -28.9% -57.3%
ROA (Net income/ Total Assets) -6.54% -6.67% -8.64% -9.82% -10.2% -14.5%
Assets 1 -45.67 20.2 9.051 -4.429 13.24 12.32
Book Value Per Share 2 0.0200 0.0100 0.0100 0.0100 0.0100 0
Cash Flow per Share 2 0.0100 0.0100 0.0100 0.0100 0 0
Capex - 0 0 - - -
Capex / Sales - - - - - -
Announcement Date 11/03/19 12/03/20 15/03/21 30/03/22 22/03/23 30/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
XTL BIOPHARMACEUTICALS LTD. Stock XTL Biopharmaceuticals Ltd.
+188.57% 14.89M
MODERNA, INC. Stock Moderna, Inc.
+29.11% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.95% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.29% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.68% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.11% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.04% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XTLB Stock
  4. Financials XTL Biopharmaceuticals Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW